In reviewing the genitourinary malignancies in the context of recent findings from ASCO 2016, including metastatic testicular, renal cell, bladder, castration-resistant prostate and urothelial cancers, David J Vaughn, MD, finds reason to be optimistic. Studies of newer agents, often in combination, are demonstrating advances over traditional standards of care, with improved quality of life and in some instances, prolonged progression-free survival and survival.
Related Links
Published
February 7, 2017
Created by
BROADCASTMED